Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?-To The Moon - Tiger Brokers Online Investing Community

Like
1
Favorite

Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?

News Direct2023-03-27

West Henrietta, NY --News Direct-- DSS, Inc. By Ernest Dela Aglanu, Benzinga Impact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

kezgtree
·2023-04-11
... another NATO in the news... lol
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2322429663?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GKRFWC1AWrdDVXk4O2Yoww--~B/aD0xMjE7dz0yNjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/news_direct/6a58ce67cc1d1afcd7e819c4400d288a","is_english":true,"pubTime":"2023-03-27 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2322429663","market":"us","top_or_hot":-1,"title":"Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?","media":"News Direct","content":"<div>\n<p>West Henrietta, NY --News Direct-- DSS, Inc.\nBy Ernest Dela Aglanu, Benzinga\nImpact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/impact-biomedical-preparing-potential-spinoff-130000522.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImpact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-27 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/impact-biomedical-preparing-potential-spinoff-130000522.html><strong>News Direct</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>West Henrietta, NY --News Direct-- DSS, Inc.\nBy Ernest Dela Aglanu, Benzinga\nImpact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/impact-biomedical-preparing-potential-spinoff-130000522.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1280957306.USD","symbol_name":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/impact-biomedical-preparing-potential-spinoff-130000522.html","article_id":"2322429663","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GKRFWC1AWrdDVXk4O2Yoww--~B/aD0xMjE7dz0yNjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/news_direct/6a58ce67cc1d1afcd7e819c4400d288a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2322429663","pubTimestamp":1679922000,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"West Henrietta, NY --News Direct-- DSS, Inc.\nBy Ernest Dela Aglanu, Benzinga\nImpact Biomedical, a bi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4087":"商业印刷","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1261432733.SGD":"Fidelity World A-ACC-SGD","SANA":"Sana Biotechnology, Inc.","JNJ":"强生","BK4512":"苹果概念","BK4023":"应用软件","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4532":"文艺复兴科技持仓","LABP":"Landos Biopharma, Inc.","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","LHDX":"Lucira Health, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技","LU0122379950.USD":"贝莱德世界健康科学A2","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4211":"区域性银行","LU0149725797.USD":"汇丰美国股市经济规模基金","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4196":"保健护理服务","BK4206":"工业集团企业","BK4082":"医疗保健设备","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4501":"段永平概念","BK4559":"巴菲特持仓","BK4588":"碎股","BK4568":"美国抗疫概念","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4550":"红杉资本持仓","DSS":"DSS Inc","GE":"GE航空航天","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","NYSE":"纽交所","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","MMM":"3M","ONTF":"ON24, Inc.","BK4581":"高盛持仓","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4504":"桥水持仓","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"translate_title":"Impact Biomedical准备潜在的分拆——这对控股公司DSS，Inc（纽约证券交易所代码：DSS）的投资者意味着什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LHDX":1,"SANA":1,"ONTF":1,"NYSE":1,"MMM":1,"LABP":1,"JNJ":1,"GE":1,"DSS":0.9},"content_text":"West Henrietta, NY --News Direct-- DSS, Inc.\nBy Ernest Dela Aglanu, Benzinga\nImpact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and conditions and one of the key businesses in the DSS Inc. (NYSE American: DSS) portfolio, is preparing for a potential spinoff that could also have implications for the pharmaceutical industry at large.\nThe success of this spinoff could present significant growth opportunities for the company. It looks to help expand the company’s ownership of a suite of antiviral and medical technologies, which was valued at $390 million in 2019 by Destum Partners, a global leader in investment and advisory services.\nThe total global pharmaceutical market was estimated at $1.48 trillion in 2022 alone, and as the sector continues to experience an upward trend, Impact Biomedical could expect to see growth opportunities.\nBut one may ask, what is the fuss about the company spinning off? A spinoff occurs when a company splits off a portion of its business into a separate company and distributes shares of the new entity tax-free to the parent company’s shareholders.\nSome prominent companies that have pursued spinoffs recently include 3M Co. (NYSE: MMM), General Electric Company (NYSE: GE), and Johnson & Johnson (NYSE: JNJ).\nThe good news is such a spinoff can increase Impact Biomedical’s valuation — and the value of DSS. In May 2020, Impact Biomedical revealed it had received a valuation of $933 million for a suite of technology from a different independent valuation firm. The valuation may go even higher, possibly presenting exciting opportunities for investors.\nOverall, the spinoff, which is still in the works, may enhance Impact Biomedical’s research leading to breakthroughs in the development of new treatments for a wide range of diseases, from cancer to infectious diseases. It is anticipated that it will enable the company to focus on its core research and development activities without any distractions resulting in faster innovation and more precise targeting of specific disease pathways.\nBy establishing a new, independent company focused exclusively on its research and development efforts, the spinoff would enable Impact Biomedical to attract new funding and investment to pursue a more aggressive growth strategy as it continues to develop its cutting-edge technologies and groundbreaking research.\nThe spinoff could warrant a close watch, especially as the company says it has established a reputation and loyal following among investors and healthcare professionals.\nDSS completed the acquisition of Impact BioMedical in August 2020. In September last year, the company dropped hints of the impending spinoff with reports suggesting that the company was expected to file an amended S-1. DSS said it aimed to IPO Impact Biomedical this year, with the valuation to be determined by the investment bankers and market demand.\nWhat could be exciting for shareholders is that the company plans to keep at least 50% of the spinoff entity, while shareholders will get a certain percentage. A number of shares will be newly issued to raise capital to support the growth of the newly public company.\nSince 2019, the company has embarked on a major transformation journey evolving into a multinational business operating within nine divisions with over 40 subsidiaries. The divisions and subsidiaries are meant to offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers but also create sustainable value and opportunities for transformation; Impact Biomedical is an opportunity for an innovative biotech pure play, and DSS is a way to access Impact and other opportunities.\nThe company has reported developing strong footings in biotechnology, product packaging, direct marketing, commercial lending, securities and investment management, alternative trading, digital transformation, secure living and alternative energy.\nImpact Biomedical’s Products And Development Pipeline\nImpact Biomedical drives mission-oriented discovery and development to pursue new products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company reports that its biopharmaceutical technologies have the potential to advance treatment in oncology, neurology, and immunology.\nA closer look at the current products and development pipeline as reported by Zacks Small-Cap Research:\nLineBacker: Multi-faceted therapeutic platform intended for metabolic, neurologic, cancer and infectious diseases. In July last year, the company executed a license agreement with ProPhase Labs Inc. (NASDAQ: PRPH) for its Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications.\nEquivir: A compound in antiviral infection treatments. Equivir/Nemovir is a novel blend of FDA Generally Recognized As Safe-eligible natural compounds which have potential antiviral effects with additional potential applications as health supplements or medication. These compounds are sourced from fruits, vegetables, and other natural substances.\nIn June of 2022, Impact BioMedical signed a license agreement with ProPhase Labs to produce and distribute Equivir, which has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks.\nLaetose: Laetose technology is derived from a unique combination of sugar and other compounds, which demonstrates the ability to inhibit the inflammatory and metabolic response of sugar alone. It is a sugar alternative that can potentially lower human glycemic indexes.\nThe company believes it is a breakthrough alternative sugar that could combat diabetes. Using Laetose in a daily diet, compared to sugar, could result in lower sugar consumption and lower glycemic index/load.\n3F: 3F is a unique formulation of specialized ingredients from botanical sources with the potential effect as an insect repellent and an antimicrobial. It can be used either as a standalone repellent or as an additive in detergents, lotions, shampoo, and other substances to provide mosquito protection. The formulation can also be used as a standalone antimicrobial or as an additive in detergents, lotions, shampoo, fabrics, and other substances.\nWith a successful IPO and spin off of Impact Biomedical, DSS shareholders would begin to realize the benefits of the company’s strategy of building shareholder value by distributing stock dividends through periodic spin offs.\nThis article was originally published on Benzinga here.\nDSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation.\nThis post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice\nContact Details\nRick Lutz- TraDigital IR\nrick@tradigitalir.com\nCompany Website\nhttps://www.dssworld.com/\nView source version on newsdirect.com: https://newsdirect.com/news/impact-biomedical-preparing-a-potential-spinoff-what-does-this-mean-for-investors-of-holding-company-dss-inc-nyse-american-dss-589762785","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9942803436,"gmtCreate":1681172045925,"gmtModify":1681172049573,"author":{"id":"3560896324059826","authorId":"3560896324059826","authorIdStr":"3560896324059826","name":"kezgtree","avatar":"https://community-static.tradeup.com/news/074a86f379e884eefb1d41461bb6b022","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3560896324059826"},"htmlText":"... another NATO in the news... lol","listText":"... another NATO in the news... lol","text":"... another NATO in the news... lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9942803436","repostId":2322429663,"repostType":2,"repost":{"id":"2322429663","pubTimestamp":1679922000,"share":"https://ttm.financial/m/news/2322429663?lang=&edition=fundamental","pubTime":"2023-03-27 21:00","market":"us","language":"en","title":"Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2322429663","media":"News Direct","summary":"West Henrietta, NY --News Direct-- DSS, Inc.\nBy Ernest Dela Aglanu, Benzinga\nImpact Biomedical, a bi","content":"<html><body><p>West Henrietta, NY --News Direct-- DSS, Inc.</p>\n<p>By Ernest Dela Aglanu, Benzinga</p>\n<p>Impact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and conditions and one of the key businesses in the <b><a href=\"https://laohu8.com/S/DSS\">DSS Inc</a>.</b> (NYSE American: DSS) portfolio, is preparing for a potential spinoff that could also have implications for the pharmaceutical industry at large.</p>\n<p>The success of this spinoff could present significant growth opportunities for the company. It looks to help expand the company’s ownership of a <em>suite</em> of antiviral and medical technologies, which was <em>valued</em> at $390 million in 2019 by Destum Partners, a global leader in investment and advisory services.</p>\n<p>The total global pharmaceutical market was <em>estimated</em> at $1.48 trillion in 2022 alone, and as the sector continues to experience an upward trend, <em>Impact Biomedical</em> could expect to see growth opportunities.</p>\n<p>But one may ask, what is the fuss about the company spinning off? A <em>spinoff</em> occurs when a company splits off a portion of its business into a separate company and distributes shares of the new entity tax-free to the parent company’s shareholders.</p>\n<p>Some prominent companies that have pursued spinoffs recently include <b><a href=\"https://laohu8.com/S/MMM\">3M</a> Co.</b> (NYSE: MMM), <b><em>General Electric Company</em></b> (NYSE: GE), and <b>Johnson &amp; Johnson</b> (NYSE: JNJ).</p>\n<p>The good news is such a spinoff can increase Impact Biomedical’s valuation — and the value of DSS. In May 2020, Impact Biomedical <em>revealed</em> it had received a valuation of $933 million for a suite of technology from a different independent valuation firm. The valuation may go even higher, possibly presenting exciting opportunities for investors.</p>\n<p>Overall, the spinoff, which is still in the works, may enhance Impact Biomedical’s research leading to breakthroughs in the development of new treatments for a wide range of diseases, from cancer to infectious diseases. It is anticipated that it will enable the company to focus on its core research and development activities without any distractions resulting in faster innovation and more precise targeting of specific disease pathways.</p>\n<p>By establishing a new, independent company focused exclusively on its research and development efforts, the spinoff would enable Impact Biomedical to attract new funding and investment to pursue a more aggressive growth strategy as it continues to develop its cutting-edge technologies and groundbreaking research.</p>\n<p>The spinoff could warrant a close watch, especially as the company says it has established a reputation and loyal following among investors and healthcare professionals.</p>\n<p>DSS completed the <em>acquisition</em> of Impact BioMedical in August 2020. In September last year, the company dropped <em>hints</em> of the impending spinoff with reports suggesting that the company was expected to file an amended S-1. DSS said it aimed to IPO Impact Biomedical this year, with the valuation to be determined by the investment bankers and market demand.</p>\n<p>What could be exciting for shareholders is that the company plans to keep at least 50% of the spinoff entity, while shareholders will get a certain percentage. A number of shares will be newly issued to raise capital to support the growth of the newly public company.</p>\n<p>Since 2019, the company has embarked on a major transformation journey evolving into a multinational business operating within nine divisions with over 40 subsidiaries. The divisions and subsidiaries are meant to offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers but also create sustainable value and opportunities for transformation; Impact Biomedical is an opportunity for an innovative biotech pure play, and DSS is a way to access Impact and other opportunities.</p>\n<p>The company has reported developing strong footings in biotechnology, product packaging, direct marketing, commercial lending, securities and investment management, alternative trading, digital transformation, secure living and alternative energy.</p>\n<h2>Impact Biomedical’s Products And Development Pipeline</h2>\n<p>Impact Biomedical drives mission-oriented discovery and development to pursue new products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company reports that its biopharmaceutical technologies have the potential to advance treatment in oncology, neurology, and immunology.</p>\n<p>A closer look at the current products and development <em>pipeline</em> as <em>reported</em> by Zacks Small-Cap Research:</p>\n<p><b>LineBacker:</b> Multi-faceted therapeutic platform intended for metabolic, neurologic, cancer and infectious diseases. In July last year, the company executed a license agreement with <b><a href=\"https://laohu8.com/S/PRPH\">ProPhase Labs</a> Inc.</b> (NASDAQ: PRPH) for its Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications.</p>\n<p><b>Equivir:</b> A compound in antiviral infection treatments. Equivir/Nemovir is a novel blend of <em>FDA Generally Recognized As Safe</em>-eligible natural compounds which have potential antiviral effects with additional potential applications as health supplements or medication. These compounds are sourced from fruits, vegetables, and other natural substances.</p>\n<p>In June of 2022, Impact BioMedical signed a license agreement with ProPhase Labs to produce and distribute Equivir, which has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks.</p>\n<p><b>Laetose:</b> Laetose technology is derived from a unique combination of sugar and other compounds, which demonstrates the ability to inhibit the inflammatory and metabolic response of sugar alone. It is a sugar alternative that can potentially lower human glycemic indexes.</p>\n<p>The company believes it is a breakthrough alternative sugar that could combat diabetes. Using Laetose in a daily diet, compared to sugar, could result in lower sugar consumption and lower glycemic index/load.</p>\n<p><b>3F:</b> 3F is a unique formulation of specialized ingredients from botanical sources with the potential effect as an insect repellent and an antimicrobial. It can be used either as a standalone repellent or as an additive in detergents, lotions, shampoo, and other substances to provide mosquito protection. The formulation can also be used as a standalone antimicrobial or as an additive in detergents, lotions, shampoo, fabrics, and other substances.</p>\n<p>With a successful IPO and spin off of Impact Biomedical, DSS shareholders would begin to realize the benefits of the company’s strategy of building shareholder value by distributing stock dividends through periodic spin offs.</p>\n<p><i>This article was originally published on Benzinga </i><i>here</i><i>.</i></p>\n<p><i>DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation.</i></p>\n<p><i>This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice</i></p>\n<h3><b>Contact Details</b></h3>\n<p>Rick Lutz- TraDigital IR</p>\n<p>rick@tradigitalir.com</p>\n<h3><b>Company Website</b></h3>\n<p>https://www.dssworld.com/</p>\n<p>View source version on newsdirect.com: https://newsdirect.com/news/impact-biomedical-preparing-a-potential-spinoff-what-does-this-mean-for-investors-of-holding-company-dss-inc-nyse-american-dss-589762785</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImpact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-27 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/impact-biomedical-preparing-potential-spinoff-130000522.html><strong>News Direct</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>West Henrietta, NY --News Direct-- DSS, Inc.\nBy Ernest Dela Aglanu, Benzinga\nImpact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/impact-biomedical-preparing-potential-spinoff-130000522.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/GKRFWC1AWrdDVXk4O2Yoww--~B/aD0xMjE7dz0yNjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/news_direct/6a58ce67cc1d1afcd7e819c4400d288a","relate_stocks":{"LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4087":"商业印刷","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1261432733.SGD":"Fidelity World A-ACC-SGD","SANA":"Sana Biotechnology, Inc.","JNJ":"强生","BK4512":"苹果概念","BK4023":"应用软件","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4532":"文艺复兴科技持仓","LABP":"Landos Biopharma, Inc.","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","LHDX":"Lucira Health, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技","LU0122379950.USD":"贝莱德世界健康科学A2","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4211":"区域性银行","LU0149725797.USD":"汇丰美国股市经济规模基金","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4196":"保健护理服务","BK4206":"工业集团企业","BK4082":"医疗保健设备","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4501":"段永平概念","BK4559":"巴菲特持仓","BK4588":"碎股","BK4568":"美国抗疫概念","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4550":"红杉资本持仓","DSS":"DSS Inc","GE":"GE航空航天","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","NYSE":"纽交所","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","MMM":"3M","ONTF":"ON24, Inc.","BK4581":"高盛持仓","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4504":"桥水持仓","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"source_url":"https://finance.yahoo.com/news/impact-biomedical-preparing-potential-spinoff-130000522.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2322429663","content_text":"West Henrietta, NY --News Direct-- DSS, Inc.\nBy Ernest Dela Aglanu, Benzinga\nImpact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and conditions and one of the key businesses in the DSS Inc. (NYSE American: DSS) portfolio, is preparing for a potential spinoff that could also have implications for the pharmaceutical industry at large.\nThe success of this spinoff could present significant growth opportunities for the company. It looks to help expand the company’s ownership of a suite of antiviral and medical technologies, which was valued at $390 million in 2019 by Destum Partners, a global leader in investment and advisory services.\nThe total global pharmaceutical market was estimated at $1.48 trillion in 2022 alone, and as the sector continues to experience an upward trend, Impact Biomedical could expect to see growth opportunities.\nBut one may ask, what is the fuss about the company spinning off? A spinoff occurs when a company splits off a portion of its business into a separate company and distributes shares of the new entity tax-free to the parent company’s shareholders.\nSome prominent companies that have pursued spinoffs recently include 3M Co. (NYSE: MMM), General Electric Company (NYSE: GE), and Johnson & Johnson (NYSE: JNJ).\nThe good news is such a spinoff can increase Impact Biomedical’s valuation — and the value of DSS. In May 2020, Impact Biomedical revealed it had received a valuation of $933 million for a suite of technology from a different independent valuation firm. The valuation may go even higher, possibly presenting exciting opportunities for investors.\nOverall, the spinoff, which is still in the works, may enhance Impact Biomedical’s research leading to breakthroughs in the development of new treatments for a wide range of diseases, from cancer to infectious diseases. It is anticipated that it will enable the company to focus on its core research and development activities without any distractions resulting in faster innovation and more precise targeting of specific disease pathways.\nBy establishing a new, independent company focused exclusively on its research and development efforts, the spinoff would enable Impact Biomedical to attract new funding and investment to pursue a more aggressive growth strategy as it continues to develop its cutting-edge technologies and groundbreaking research.\nThe spinoff could warrant a close watch, especially as the company says it has established a reputation and loyal following among investors and healthcare professionals.\nDSS completed the acquisition of Impact BioMedical in August 2020. In September last year, the company dropped hints of the impending spinoff with reports suggesting that the company was expected to file an amended S-1. DSS said it aimed to IPO Impact Biomedical this year, with the valuation to be determined by the investment bankers and market demand.\nWhat could be exciting for shareholders is that the company plans to keep at least 50% of the spinoff entity, while shareholders will get a certain percentage. A number of shares will be newly issued to raise capital to support the growth of the newly public company.\nSince 2019, the company has embarked on a major transformation journey evolving into a multinational business operating within nine divisions with over 40 subsidiaries. The divisions and subsidiaries are meant to offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers but also create sustainable value and opportunities for transformation; Impact Biomedical is an opportunity for an innovative biotech pure play, and DSS is a way to access Impact and other opportunities.\nThe company has reported developing strong footings in biotechnology, product packaging, direct marketing, commercial lending, securities and investment management, alternative trading, digital transformation, secure living and alternative energy.\nImpact Biomedical’s Products And Development Pipeline\nImpact Biomedical drives mission-oriented discovery and development to pursue new products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company reports that its biopharmaceutical technologies have the potential to advance treatment in oncology, neurology, and immunology.\nA closer look at the current products and development pipeline as reported by Zacks Small-Cap Research:\nLineBacker: Multi-faceted therapeutic platform intended for metabolic, neurologic, cancer and infectious diseases. In July last year, the company executed a license agreement with ProPhase Labs Inc. (NASDAQ: PRPH) for its Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications.\nEquivir: A compound in antiviral infection treatments. Equivir/Nemovir is a novel blend of FDA Generally Recognized As Safe-eligible natural compounds which have potential antiviral effects with additional potential applications as health supplements or medication. These compounds are sourced from fruits, vegetables, and other natural substances.\nIn June of 2022, Impact BioMedical signed a license agreement with ProPhase Labs to produce and distribute Equivir, which has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks.\nLaetose: Laetose technology is derived from a unique combination of sugar and other compounds, which demonstrates the ability to inhibit the inflammatory and metabolic response of sugar alone. It is a sugar alternative that can potentially lower human glycemic indexes.\nThe company believes it is a breakthrough alternative sugar that could combat diabetes. Using Laetose in a daily diet, compared to sugar, could result in lower sugar consumption and lower glycemic index/load.\n3F: 3F is a unique formulation of specialized ingredients from botanical sources with the potential effect as an insect repellent and an antimicrobial. It can be used either as a standalone repellent or as an additive in detergents, lotions, shampoo, and other substances to provide mosquito protection. The formulation can also be used as a standalone antimicrobial or as an additive in detergents, lotions, shampoo, fabrics, and other substances.\nWith a successful IPO and spin off of Impact Biomedical, DSS shareholders would begin to realize the benefits of the company’s strategy of building shareholder value by distributing stock dividends through periodic spin offs.\nThis article was originally published on Benzinga here.\nDSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation.\nThis post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice\nContact Details\nRick Lutz- TraDigital IR\nrick@tradigitalir.com\nCompany Website\nhttps://www.dssworld.com/\nView source version on newsdirect.com: https://newsdirect.com/news/impact-biomedical-preparing-a-potential-spinoff-what-does-this-mean-for-investors-of-holding-company-dss-inc-nyse-american-dss-589762785","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}